Author

R. Houtman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1

Frequent Co-Authors

E. A. Ortlund· 3 shared J. C. Nwachukwu· 3 shared K. W. Nettles· 3 shared C. C. Nettles· 2 shared D. Melchers· 2 shared E. H. D'Agostino· 2 shared J. A. Katzenellenbogen· 2 shared J. L. Cornelison· 2 shared

Activity by Year

2018-2020 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

E. A. Ortlund

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Tapping into a phospholipid-LRH-1 axis yields a powerful anti-inflammatory agent with in vivo activity against colitis

S. G. Mays, E. H. D'Agostino, A. R. Flynn, X. Huang, G. Wang, X. Liu, E. J. Millings, C. D. Okafor, A. Patel, M. L. Cato, J. L. Cornelison, D. Melchers, R. Houtman, D. D. Moore, J. W. Calvert, , E. A. Ortlund

The paper develops a phospholipid-mimicking LRH-1 agonist that shows in vivo efficacy in a colitis model by improving binding affinity and transcriptional activity.

bioRxiv · Sep 1, 2020 · PreprintBiochemistry

Dual mechanism estrogen receptor inhibitors

J. Min, J. C. Nwachukwu, S. Srinivasan, E. Rangarajan, C. C. Nettles, V. Sanabria Guillen, Y. Ziegler, S. Yan, K. Carlson, Y. Hou, S. H. Kim, S. Novick, B. Pascal, R. Houtman, P. Griffin, , K. W. Nettles

This paper develops dual-mechanism ER inhibitors that use two distinct targeting moieties to suppress ER activity in breast cancer cells and resistance models.

bioRxiv · Jul 6, 2020Cancer Biology

Chemical Systems Biology Reveals Mechanisms of Glucocorticoid Receptor Signaling

N. Bruno, J. C. Nwachukwu, S. Srinivasan, C. C. Nettles, T. Izard, z. Jin, S. Boregowda, D. Phinney, O. Elemento, X. Liu, E. A. Ortlund, R. Houtman, D. Stavreva, G. Hager, T. Kamencka, , K. W. Nettles

The paper uses Ligand Class Analysis to identify target genes and coregulator interactions of glucocorticoid receptor ligands, revealing mechanisms linking ligand structure to physiological outcomes.

bioRxiv · Jun 15, 2020Pharmacology & Toxicology

Development of a new class of liver receptor homolog-1 (LRH-1) agonists by photoredox conjugate addition

J. L. Cornelison, M. L. Cato, A. M. Johnson, E. H. D'Agostino, D. Melchers, A. B. Patel, S. G. Mays, R. Houtman, E. A. Ortlund, N. T. Jui

This study develops a new class of LRH-1 agonists using a photoredox conjugate addition method, enabling bridgehead substitution to enhance ligand activation.

bioRxiv · Mar 16, 2020Biochemistry

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells

S. W. Fanning, R. Jeselsohn, V. Dharmarajan, C. G. Mayne, M. Karimi, G. Buchwalter, R. Houtman, W. Toy, C. E. Fowler, M. Laine, K. E. Carlson, T. A. Martin, J. Nowak, J. C. Nwachukwu, D. J. Hosfield, , G. L. Greene

This study shows that bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells by inhibiting Y537S and D538G ER mutants more effectively than tamoxifen.

bioRxiv · Apr 23, 2018Cancer Biology